Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

In vivo characterization of the physiological function of ATXN1 and its paralog ATXN1L in the mature nervous system.

EF 2012-13

Résumé
Spinocerebellar ataxia type 1 (SCA1) - one of nine familial disorders that are caused by expansion of a tract of glutamines - is a devastating neurodegenerative disease affecting individuals in their second to fourth decade of life. The expanded amino acid tract in the protein ATAXIN-1 (ATXN1) alters its shape (misfold) and interactions with other proteins, which causes it to accumulate and become toxic to cells. Understanding the role of ATXN1 in cells and what it interacts with is critical to understanding the disease. Another ATXN1 family member, named ATAXIN1-Like (ATXN1L), can interact with ATXN1 and can compete with the mutant form to prevent its toxicity in mice. A principal goal in the field of polyglutamine diseases is to grasp the mechanisms governing the misfolding of proteins so as to develop effective therapies. Therefore, uncovering the normal function(s) of ATXN1 and ATXN1L within neurons, particularly in the adult brain, is critical to understanding how glutamine expansion induces neurotoxicity. This study proposes to uncover the physiological role of ATXN1 and ATXN1L in adult mice. To do so, we will characterize the functions of ATXN1 and ATXN1L in the mature mouse nervous system first by deleting them in adult animals and then looking at what happens to brain cells as a result. We will evaluate which proteins and RNAs change in brain cells when ATAXN1 and ATXN1L are deleted and pinpoint which of these changes can mediate neurotoxicity. These experiments will identify molecular pathways involved in the physiological functions of these proteins and might reveal changes that are amenable for targeted treatment. Collectively, these findings are expected to uncover the roles of ATXN1 family members within the brain and expose plausible mechanisms whose deregulation results in SCA1. Likewise, discoveries made from this research stand to inform about other polyglutamine diseases.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Texas, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
269945
Name
Rousseaux Maxime W
Region
Texas
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
In vivo characterization of the physiological function of ATXN1 and its paralog ATXN1L in the mature nervous system.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Animal Models; Atxn1; Atxn1l; Behavioral Tests; Neuroanatomy/Histopathology; Neurodegeneration; Next Generation Sequencing; Polyglutamine Disease; Spinocerebellar Ataxia; Tamoxifen-Inducible Cre
Abstract
Spinocerebellar ataxia type 1 (SCA1) - one of nine familial disorders that are caused by expansion of a tract of glutamines - is a devastating neurodegenerative disease affecting individuals in their second to fourth decade of life. The expanded amino acid tract in the protein ATAXIN-1 (ATXN1) alters its shape (misfold) and interactions with other proteins, which causes it to accumulate and become toxic to cells. Understanding the role of ATXN1 in cells and what it interacts with is critical to understanding the disease. Another ATXN1 family member, named ATAXIN1-Like (ATXN1L), can interact with ATXN1 and can compete with the mutant form to prevent its toxicity in mice. A principal goal in the field of polyglutamine diseases is to grasp the mechanisms governing the misfolding of proteins so as to develop effective therapies. Therefore, uncovering the normal function(s) of ATXN1 and ATXN1L within neurons, particularly in the adult brain, is critical to understanding how glutamine expansion induces neurotoxicity. This study proposes to uncover the physiological role of ATXN1 and ATXN1L in adult mice. To do so, we will characterize the functions of ATXN1 and ATXN1L in the mature mouse nervous system first by deleting them in adult animals and then looking at what happens to brain cells as a result. We will evaluate which proteins and RNAs change in brain cells when ATAXN1 and ATXN1L are deleted and pinpoint which of these changes can mediate neurotoxicity. These experiments will identify molecular pathways involved in the physiological functions of these proteins and might reveal changes that are amenable for targeted treatment. Collectively, these findings are expected to uncover the roles of ATXN1 family members within the brain and expose plausible mechanisms whose deregulation results in SCA1. Likewise, discoveries made from this research stand to inform about other polyglutamine diseases.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rousseaux, Maxime W
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~